

# Marc Peeters

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9560206/marc-peeters-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

16,457  
citations

52  
h-index

125  
g-index

257  
ext. papers

18,678  
ext. citations

5.7  
avg, IF

6  
L-index

#	Paper	IF	Citations
239	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.. <i>Pharmacology &amp; Therapeutics</i> , <b>2022</b> , 108107	13.9	4
238	Excellent Response to MEK Inhibition in an Gene Fusion Driven Carcinoma: Case Report and Literature Review.. <i>Anticancer Research</i> , <b>2022</b> , 42, 373-379	2.3	0
237	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <i>Medicinal Research Reviews</i> , <b>2022</b> , 42, 112-155	14.4	9
236	Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. <i>Cells</i> , <b>2021</b> , 10,	7.9	6
235	Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
234	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 328-339	7.5	5
233	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 213	12.8	5
232	Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. <i>Redox Biology</i> , <b>2021</b> , 42, 101949	11.3	19
231	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252646	3.7	
230	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 859-867	3.9	7
229	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103190	7	0
228	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 162-172	3.7	16
227	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	14
226	The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1366-1372	8.7	3
225	Safety and Antitumor Activity of EPD-L1 Antibody as Monotherapy or in Combination with TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6393-6404	12.9	7
224	Expression profiles of miR-196, miR-132, miR-146a, and miR-134 in human colorectal cancer tissues in accordance with their clinical significance : Comparison regarding KRAS mutation. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 1162-1170	2.3	
223	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An Study on a Novel Combination Strategy. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 697967	5.3	1

222	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 737311	8.4	6
221	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , <b>2021</b> , 17, 3881-3892	3.6	0
220	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 752-761	8.7	7
219	A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial. <i>Breast</i> , <b>2020</b> , 53, 23-32	3.6	4
218	DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
217	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 251-270	3.5	3
216	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial). <i>Trials</i> , <b>2020</b> , 21, 237	2.8	4
215	Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform. <i>ESMO Open</i> , <b>2020</b> , 5, e000817	6	10
214	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPCCCT and WJOG6510G. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
213	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready or Able to Improve Clinical Outcome?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
212	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , <b>2020</b> , 24, 113-124	4.5	15
211	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , <b>2020</b> , 25, e1-e4	5.7	5
210	The immunologic aspects in hormone receptor positive breast cancer. <i>Cancer Treatment and Research Communications</i> , <b>2020</b> , 25, 100207	2	1
209	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 891-898	4.6	7
208	Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	14
207	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 89, 102068	14.4	42
206	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , <b>2020</b> , 5,	6	18
205	High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 225-227	7.5	3

204	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , <b>2020</b> , 25, e1428-e1432	5.7	2
203	Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1165	6.8	13
202	The art of obtaining a high yield of cell-free DNA from urine. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231058	3.7	19
201	Determination of the Potential Tumor-Suppressive Effects of in a Chemically Induced and in a Genetically Modified Intestinal Cancer Mouse Model. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
200	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 245-256.e5	3.8	0
199	Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4
198	Towards risk-stratified colorectal cancer screening. Adding risk factors to the fecal immunochemical test: Evidence, evolution and expectations. <i>Preventive Medicine</i> , <b>2019</b> , 126, 105746	4.3	8
197	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
196	Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer. <i>Cancer Medicine</i> , <b>2019</b> , 8, 2133-2145	4.8	28
195	In Vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , <b>2019</b> , 13, 1196-1213	7.9	8
194	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. <i>Cancers</i> , <b>2019</b> , 11,	6.6	42
193	Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. <i>Head and Neck</i> , <b>2019</b> , 41, 2197-2207	4.2	10
192	Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2019</b> , 20, 333-351	10.5	6
191	Should Flanders consider lowering its target age for colorectal cancer screening to 45-49?. <i>Cancer Epidemiology</i> , <b>2019</b> , 61, 172-175	2.8	1
190	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , <b>2019</b> , 79, 1375-1394	12.1	29
189	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	40
188	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2019</b> , 26, R109-R130	5.7	13
187	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4

186	The Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
185	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1216-1225	12.9	18
184	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , <b>2019</b> , 108, 26-36	5.6	25
183	Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. <i>Oncotmmunology</i> , <b>2018</b> , 7, e1440167	7.2	12
182	Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e369-e379	3.8	30
181	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 339-349	3.5	6
180	Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. <i>Molecular Oncology</i> , <b>2018</b> , 12, 830-854	7.9	27
179	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 471-478	4.2	5
178	Large-scale analysis of methylation reveals its potential as biomarker for breast cancer. <i>Clinical Epigenetics</i> , <b>2018</b> , 10, 51	7.7	52
177	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , <b>2018</b> , 14, 1629-1645	3.6	14
176	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 170-178.e3	3.8	31
175	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with wild-type metastatic colorectal carcinoma. <i>ESMO Open</i> , <b>2018</b> , 3, e000297	6	15
174	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 321-335	4.9	19
173	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kline Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 50-57.e8	3.8	5
172	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1 $\alpha$ and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. <i>Cancers</i> , <b>2018</b> , 10,	6.6	35
171	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 303-312	8.7	17
170	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 991-1006	9.5	31
169	Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 2001-2010	4.9	13

168	Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme. <i>Cancer Epidemiology</i> , <b>2018</b> , 56, 90-96	2.8	7
167	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e617-e629	3.8	31
166	Impact of Emergent Circulating Tumor DNA Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5602-5609	12.9	25
165	Tumorbank@uza: A Collection of Tissue, Fluid Samples and Associated Data of Oncology Patients for the Use in Translational Research. <i>Open Journal of Bioresources</i> , <b>2018</b> , 5,	0.9	6
164	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1407899	7.2	24
163	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 121, 1-10	7	35
162	Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 467	5.3	17
161	Indications for Locoregional Tumor Therapies: CRC Liver Metastases <b>2018</b> , 83-106		
160	Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. <i>Tumor Biology</i> , <b>2017</b> , 39, 1010428317694327	2.9	16
159	An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 2823-2832	3.9	4
158	Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage I rectal cancer: A real standard?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 114, 43-52	7	27
157	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3417-3423	3.9	6
156	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. <i>Targeted Oncology</i> , <b>2017</b> , 12, 97-109	5	37
155	SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2154-2162	4.5	4
154	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the Mutation Status and Hypoxia. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1441-1452	4.5	10
153	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2017</b> , 32, 229-238	3.9	12
152	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6411-6420	12.9	27
151	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1159-1171	21.7	193

150	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECURSE trial. <i>ESMO Open</i> , <b>2017</b> , 2, e000261	6	16
149	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 16-24	7.5	28
148	Exosomes in lung cancer liquid biopsies: Two sides of the same coin?. <i>Lung Cancer</i> , <b>2017</b> , 104, 134-135	5.9	7
147	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	33
146	Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3507-3507	2.2	13
145	Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3523-3523	2.2	2
144	Clinical outcomes and emergent circulating tumor (ct)DNA RAS mutations and allele fraction for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3584-3584	2.2	2
143	BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pre) with BRAFV600E mCRC. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TP53677, TP57677	2.2	3
142	DFNA5 promoter methylation a marker for breast tumorigenesis. <i>Oncotarget</i> , <b>2017</b> , 8, 31948-31958	3.3	25
141	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. <i>Oncotarget</i> , <b>2017</b> , 8, 56968-56979	3.3	42
140	Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena. <i>Minerva Surgery</i> , <b>2017</b> , 72, 206-218	0.1	
139	Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLTL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3554-3554	2.2	
138	Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11569-11569	2.2	29
137	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2017</b> , 32, 229-238	3.9	6
136	Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients Plasma Through qPCR: A Feasible Liquid Biopsy Tool. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	38
135	Cachexia in cancer: what is in the definition?. <i>BMJ Open Gastroenterology</i> , <b>2016</b> , 3, e000097	3.9	61
134	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 650-8	8.7	52
133	APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , <b>2016</b> , 375, 313-322	9.9	43

132	Reducing Compounds Equivocally Influence Oxidation during Digestion of a High-Fat Beef Product, which Promotes Cytotoxicity in Colorectal Carcinoma Cell Lines. <i>Journal of Agricultural and Food Chemistry</i> , <b>2016</b> , 64, 1600-9	5.7	28
131	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1723-31	2.2	229
130	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. <i>Oncologist</i> , <b>2016</b> , 21, 59-71	5.7	12
129	Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23035-e23035	2.2	7
128	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. <i>Oncotarget</i> , <b>2016</b> , 7, 73960-73970	3.3	13
127	Multidisciplinary management of patients with liver metastasis from colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 7215-25	5.6	49
126	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3538-3538	2.2	
125	Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. <i>Oncotarget</i> , <b>2016</b> , 7, 48625-48643	3.3	42
124	Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. <i>Oncotarget</i> , <b>2016</b> , 7, 28748-60	3.3	73
123	Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 523-530	4.5	22
122	Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 3567-71	3.9	9
121	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 51-59	7.5	42
120	Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1231-42	7.5	53
119	Engineering monocyte-derived dendritic cells to secrete interferon- $\gamma$ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 831-42	7.4	26
118	Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. <i>Drugs</i> , <b>2015</b> , 75, 731-48	12.1	13
117	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1909-19	59.2	720
116	Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. <i>Current Treatment Options in Oncology</i> , <b>2015</b> , 16, 18	5.4	7
115	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1493-500	5.9	81



114	Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. <i>Drugs</i> , <b>2015</b> , 75, 1739-56	12.1	6
113	Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5469-79	12.9	125
112	Next generation exome sequencing of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1 reveals different lineages. <i>Cancer Genetics</i> , <b>2015</b> , 208, 523	2.3	11
111	The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. <i>BMC Research Notes</i> , <b>2015</b> , 8, 203	2.3	19
110	Cancer and the microbiome: potential applications as new tumor biomarker. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 317-30	3.5	32
109	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. <i>Cancer Letters</i> , <b>2015</b> , 356, 872-9	9.9	22
108	Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?. <i>Trials</i> , <b>2015</b> , 16, 395	2.8	19
107	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138341	3.7	12
106	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. <i>Gastroenterology Research and Practice</i> , <b>2015</b> , 2015, 650846	2	3
105	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 22666-79	3.3	54
104	Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. <i>Journal of Molecular Endocrinology</i> , <b>2015</b> , 54, 137-47	4.5	56
103	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 1921-38	4.4	17
102	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , <b>2015</b> , 6, 24780-96	3.3	70
101	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 569-79	21.7	314
100	The role of targeted therapy for gastrointestinal tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 875-85	4.2	22
99	Liquid biopsies in lung cancer: the new ambrosia of researchers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 539-46	11.2	95
98	ASPECCT: panitumumab versus cetuximab for colorectal cancer--authorsReply. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e303	21.7	2
97	The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. <i>BMC Cancer</i> , <b>2014</b> , 14, 594	4.8	6

96	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <i>BMC Research Notes</i> , <b>2014</b> , 7, 337	2.3	29
95	Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. <i>Cancer Letters</i> , <b>2014</b> , 354, 365-77	9.9	45
94	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 990-1004	14.4	60
93	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. <i>Current Colorectal Cancer Reports</i> , <b>2014</b> , 10, 380-394	1	1
92	Case histories in unresectable liver-dominant metastatic colorectal cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 41-7	3.6	0
91	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , <b>2014</b> , 15, e582-e583	21.7	2
90	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3568-3568	2.2	27
89	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA387-LBA387	2.2	20
88	Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 69-81	0.8	19
87	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. <i>BMC Cancer</i> , <b>2013</b> , 13, 190	4.8	7
86	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 250-260	1	1
85	An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. <i>Targeted Oncology</i> , <b>2013</b> , 8, 127-36	5	25
84	Antineoplastic therapy-induced pulmonary toxicity. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 997-1006	9.6	6
83	Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 380-390	1	6
82	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1902-12	12.9	192
81	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 759-65	2.2	189
80	Expression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples. <i>Diagnostic Molecular Pathology</i> , <b>2013</b> , 22, 59-64		21
79	Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. <i>European Journal of Cancer Prevention</i> , <b>2013</b> , 22, 46-51	2	58

78	Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. <i>Oncologist</i> , <b>2013</b> , 18, 850-64	5.7	70
77	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 907-917	3.3	21
76	Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3617-3617	2.2	28
75	The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 907-917	3.3	12
74	The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 2186-94	3.1	83
73	Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 397-406	14.4	61
72	Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 14-23	3.8	17
71	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , <b>2012</b> , 12, 144	4.8	13
70	Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members. <i>BMC Cancer</i> , <b>2012</b> , 12, 515	4.8	7
69	Future directions for selective internal radiation therapy in colorectal cancer. <i>European Journal of Cancer, Supplement</i> , <b>2012</b> , 10, 15-17	1.6	3
68	Will the medical student in the team please stand up?. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 757-8	21.7	1
67	Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. <i>PLoS ONE</i> , <b>2012</b> , 7, e46536	3.7	204
66	Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 2842-52	3.1	147
65	Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2861-8	2.2	99
64	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 19, 907-917	3.3	3
63	Single-Photon Emission Computed Tomographic Imaging of the Early Time Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl His-Annexin A5 in a Colorectal Cancer Xenograft Model. <i>Molecular Imaging</i> , <b>2012</b> , 11, 7290.2011.00034	3.7	19
62	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , <b>2011</b> , 378, 2005-2012	4.0	768
61	In vivo imaging of apoptosis in oncology: an update. <i>Molecular Imaging</i> , <b>2011</b> , 10, 340-58	3.7	34

60	EGFR in melanoma: clinical significance and potential therapeutic target. <i>Journal of Cutaneous Pathology</i> , <b>2011</b> , 38, 492-502	1.7	58
59	MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2011</b> , 458, 197-203	5.1	12
58	Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. <i>International Journal of Colorectal Disease</i> , <b>2011</b> , 26, 173-81	3	28
57	Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , <b>2011</b> , 24, 225-32	2.8	14
56	Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 558-66	4	10
55	Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. <i>Radiation Research</i> , <b>2011</b> , 175, 10-20	3.1	14
54	The presence of Y chromosomal deoxyribonucleic acid in the female vaginal swab: possible implications for human papillomavirus testing. <i>Cancer Epidemiology</i> , <b>2011</b> , 35, 101-3	2.8	9
53	Expression analysis on archival material: comparison of 5 commercially available RNA isolation kits for FFPE material. <i>Diagnostic Molecular Pathology</i> , <b>2011</b> , 20, 203-11		12
52	Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. <i>Clinical and Developmental Immunology</i> , <b>2011</b> , 2011, 565187		93
51	(99mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1786-94	8.9	34
50	Digestive oncologist in the gastroenterology training curriculum. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 1109-15	5.6	4
49	Cardiovascular risk status can influence the colorectal cancer screening strategy. <i>Digestion</i> , <b>2010</b> , 81, 18-9	3.6	
48	Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. <i>Oncologist</i> , <b>2010</b> , 15, 308-16	5.7	20
47	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4706-13	2.2	789
46	Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4450-6	2.2	200
45	Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. <i>Future Oncology</i> , <b>2010</b> , 6, 1485-96	3.6	20
44	Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3687-94	2.2	311
43	In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. <i>Nuclear Medicine and Biology</i> , <b>2010</b> , 37, 965-75	2.1	17

42	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. <i>BMC Cancer</i> , <b>2010</b> , 10, 189	4.8	58
41	Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. <i>Cancer</i> , <b>2010</b> , 116, 5200-6	6.4	48
40	Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyond ERAS that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) <b>2010</b> ,		6
39	Combined effect of EPO and radiotherapy on the expression of endogenous molecular markers of tumor metabolism and metastasis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2009</b> , 24, 565-72	3.9	
38	Forcing cancer cells to commit suicide. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2009</b> , 24, 395-407	3.9	23
37	Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. <i>Oncologist</i> , <b>2009</b> , 14, 29-39	5.7	60
36	Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2913-9	12.9	167
35	Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. <i>BMC Cancer</i> , <b>2009</b> , 9, 112	4.8	37
34	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i> , <b>2009</b> , 115, 1544-54	6.4	114
33	Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 665-72	3.5	20
32	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5068-74	2.2	284
31	Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. <i>Oncology Reports</i> , <b>2009</b> , 22, 105-13	3.5	19
30	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 2288-95	7.5	18
29	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5869-78	12.9	154
28	Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. <i>Cancer Investigation</i> , <b>2008</b> , 26, 852-9	2.1	61
27	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1626-34	2.2	2666
26	Unusual serum electrophoresis pattern in a woman with pancreatic carcinoma. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1572-4; discussion 1574-5	5.5	4
25	Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 535-41	3.1	60

24	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1658-64	2.2	1611
23	Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 424-31	3.1	16
22	Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2007</b> , 66, 391-7	5.7	46
21	Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 1188-96	4	52
20	Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 62, 1351-6	4	22
19	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. <i>Gastroenterology</i> , <b>2003</b> , 125, 1235-45	13.3	25
18	The value of serologic markers in indeterminate colitis: a prospective follow-up study. <i>Gastroenterology</i> , <b>2002</b> , 122, 1242-7	13.3	285
17	Tc-99m HMPAO white blood cell scintigraphy in the assessment of the extent and severity of an acute exacerbation of ulcerative colitis. <i>Clinical Nuclear Medicine</i> , <b>2001</b> , 26, 99-104	1.7	17
16	Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. <i>Inflammatory Bowel Diseases</i> , <b>2001</b> , 7, 8-15	4.5	126
15	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. <i>Gastroenterology</i> , <b>2001</b> , 120, 834-40	13.3	39
14	Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. <i>Gastroenterology</i> , <b>2001</b> , 120, 827-33	13.3	118
13	Inflammatory bowel disease in spouses and their offspring. <i>Gastroenterology</i> , <b>2001</b> , 120, 816-9	13.3	92
12	Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. <i>Gastroenterology</i> , <b>2001</b> , 120, 1323-9	13.3	318
11	Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 730-4	0.7	306
10	Genetic-wide scanning in a Belgian IBD population reveals novel linkages and validates previous linkages. <i>Gastroenterology</i> , <b>2001</b> , 120, A456	13.3	2
9	Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. <i>Annals of Surgery</i> , <b>2000</b> , 232, 743-52	7.8	206
8	Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity. <i>Inflammatory Bowel Diseases</i> , <b>2000</b> , 6, 165-70	4.5	19
7	Familial and sporadic inflammatory bowel disease: different entities?. <i>Inflammatory Bowel Diseases</i> , <b>2000</b> , 6, 314-20	4.5	31

6	Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. <i>Journal of Parenteral and Enteral Nutrition</i> , <b>1999</b> , 23, 7-11	4.2	86
5	Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1999</b> , 26, 1560-6	8.8	51
4	Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. <i>Gastroenterology</i> , <b>1999</b> , 116, 22-8	13.3	399
3	Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1998</b> , 25, 1293-9	8.8	71
2	Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. <i>Gastroenterology</i> , <b>1995</b> , 108, 1617-21	13.3	638
1	Increased permeability of macroscopically normal small bowel in Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>1994</b> , 39, 2170-6	4	63